Anika Therapeutics, Inc.
ANIKAnika Therapeutics, Inc. in brief
Anika Therapeutics, Inc. is a listed company in the Biotechnology industry, based in Bedford, Massachusetts, USA. Its market value was $267 M on 30 September 2026, which makes it the 15,212th largest listed company in the world and the 2,963rd largest in the USA on this site. In the year to December 2025 it had sales of $113 M and a net loss of $11 M. It employs about 297 people and Stephen D. Griffin is its chief executive. Its largest product and service lines by sales in 2025 were OEM Channel (57%) and Commercial Channel (43%). By market, the largest shares of its 2025 sales came from USA (62%) and Europe (20%). Its shares trade under the symbol ANIK (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Anika Therapeutics, Inc.
Anika offers a broad spectrum of therapeutic treatments ranging from osteoarthritis pain management to joint preservation and restoration. Its proprietary technology is based on hyaluronic acid (HA), a naturally occurring polymer found throughout the body vital for proper joint health and tissue function.
Anika Therapeutics, Inc. timeline
- 1996
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- ✎Renamed Anika Therapeutics IncFormerly Anika Research Inc.
- 2019
- 💰Record net income of $27 millionFY2019, the highest profit of the 3 years on record.
- 2021
- 💰Record revenue of $148 millionFY2021, the highest of the 8 years on record.
Events of Anika Therapeutics, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #2,185 (Jan 2020) · #2,552 (Jan 2021) · #3,269 (Jan 2022) · #2,820 (Dec 2022) · #3,018 (Jul 2023) · #2,844 (Jan 2024) · #1,728 (Mar 2026) · #2,895 (Aug 2026) · #2,962 (Sep 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 2.2×
- Price / book
- 1.9×
- Free cash flow yield
- 1.6%
- Net margin (TTM)
- -1.4%
- Operating margin
- -9.8%
- Return on equity
- -1.2%
- Liabilities / assets
- 24.6%
- Net debt
- $-157M
- Revenue growth
- -5.9%
- R&D / revenue
- 22.8%
- Revenue per employee
- $380 K
- Profit per employee
- $-37 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $113M | -5.9% | $-11M | $-11M | -9.6% |
| Dec 2024 | $120M | -0.7% | $-5M | $-56M | -47.0% |
| Dec 2023 | $121M | +6.1% | $1M | $-83M | -68.4% |
| Dec 2022 | $114M | -23.0% | $4M | $-15M | -13.1% |
| Dec 2021 | $148M | +13.3% | $3M | $4M | 2.8% |
| Dec 2020 | $130M | +13.8% | $-28M | $-24M | -18.4% |
| Dec 2019 | $115M | +8.6% | $34M | $27M | 23.7% |
| Dec 2018 | $106M | — | $22M | $19M | 17.7% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $11M | $7M | $4M | $-0.76 | — |
| Dec 2024 | $5M | $8M | $-2M | $-3.83 | — |
| Dec 2023 | $-2M | $5M | $-7M | $-5.64 | — |
| Dec 2022 | $4M | $7M | $-3M | $-1.02 | — |
| Dec 2021 | $8M | $5M | $3M | $0.28 | — |
| Dec 2020 | $13M | $2M | $11M | $-1.69 | — |
| Dec 2019 | $37M | $3M | $34M | $1.89 | — |
| Dec 2018 | $35M | $5M | $30M | $1.27 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $31M (+10.0% on a year earlier), net income $-0M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 6, 202610-QQuarterly report · period to Sep 2026
- Nov 6, 20268-KCurrent reportResults of operations
- Jul 29, 202610-QQuarterly report · period to Jun 2026
- Jul 29, 20268-KCurrent reportResults of operations
- Jul 14, 20268-KCurrent reportMaterial agreement · New financial obligation
- Jun 23, 20268-KCurrent reportDirectors or officers changed · Shareholder vote
- Apr 30, 202610-QQuarterly report · period to Mar 2026
- Apr 29, 20268-KCurrent reportResults of operations · Directors or officers changed
- Apr 28, 2026DEF 14AProxy statement
- Mar 3, 202610-KAnnual report · period to Dec 2025
- Feb 26, 20268-KCurrent reportResults of operations · Directors or officers changed
- Jan 8, 20268-KCurrent reportResults of operations · Directors or officers changed
Official filings of Anika Therapeutics, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $113 M
- Operating income
- $-11 M
- Net income
- $-11 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $190 M
- Total liabilities
- $47 M
- Total equity
- $143 M
As of December-2025
Top 100 institutional investors in Anika Therapeutics, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Caligan Partners LP | 1,435,130 | 0 (0.00%) | 10.71% | $28 M | Nov 16, 2026 |
| 2 | BlackRock, Inc. | 1,411,066 | -38,605 (-2.66%) | 10.53% | $28 M | Nov 13, 2026 |
| 3 | Morgan Stanley | 626,369 | +12,049 (+1.96%) | 4.68% | $12 M | Nov 13, 2026 |
| 4 | Acadian Asset Management LLC | 606,544 | 0 (0.00%) | 4.53% | $12 M | Nov 9, 2026 |
| 5 | Vanguard Capital Management LLC | 565,908 | -6,205 (-1.08%) | 4.22% | $11 M | Nov 13, 2026 |
| 6 | Boothbay Fund Management, LLC | 529,626 | -14 (0.00%) | 3.95% | $10 M | Nov 16, 2026 |
| 7 | Dimensional Fund Advisors LP | 461,864 | +10,769 (+2.39%) | 3.45% | $9 M | Nov 4, 2026 |
| 8 | Renaissance Technologies LLC | 458,717 | -22,700 (-4.72%) | 3.42% | $9 M | Nov 12, 2026 |
| 9 | Geode Capital Management, LLC | 419,172 | +87,595 (+26.42%) | 3.13% | $8 M | Nov 6, 2026 |
| 10 | AQR Capital Management LLC | 400,986 | -158,860 (-28.38%) | 2.99% | $8 M | Nov 16, 2026 |
| 11 | Capital Management Corp /va | 379,436 | -69,038 (-15.39%) | 2.83% | $7 M | Oct 29, 2026 |
| 12 | Deutsche Bank AG\ | 352,134 | -1,418 (-0.40%) | 2.63% | $7 M | Nov 6, 2026 |
| 13 | State Street Corp | 309,452 | -2,444 (-0.78%) | 2.31% | $6 M | Nov 12, 2026 |
| 14 | Arrowstreet Capital, Limited Partnership | 255,568 | +148,924 (+139.65%) | 1.91% | $5 M | Nov 13, 2026 |
| 15 | Goldman Sachs Group Inc | 242,404 | +4,682 (+1.97%) | 1.81% | $5 M | Nov 16, 2026 |
| 16 | D. E. Shaw & Co., Inc. | 217,586 | -27,480 (-11.21%) | 1.62% | $4 M | Nov 16, 2026 |
| 17 | Two Sigma Investments, LP | 214,854 | -38,110 (-15.07%) | 1.60% | $4 M | Nov 16, 2026 |
| 18 | Nuveen, LLC | 166,522 | +9,984 (+6.38%) | 1.24% | $3 M | Nov 10, 2026 |
| 19 | Quantinno Capital Management LP | 155,337 | +80 (+0.05%) | 1.16% | $3 M | Nov 13, 2026 |
| 20 | Hillsdale Investment Management Inc. | 155,221 | +16,400 (+11.81%) | 1.16% | $3 M | Nov 12, 2026 |
| 21 | Jacobs Levy Equity Management, Inc | 153,285 | -64,245 (-29.53%) | 1.14% | $3 M | Nov 16, 2026 |
| 22 | Globeflex Capital L P | 139,103 | +51,503 (+58.79%) | 1.04% | $3 M | Nov 16, 2026 |
| 23 | Qube Research & Technologies Ltd | 118,076 | New | 0.88% | $2 M | Nov 13, 2026 |
| 24 | Charles Schwab Investment Management Inc | 117,414 | +4,040 (+3.56%) | 0.88% | $2 M | Nov 16, 2026 |
| 25 | Northern Trust Corp | 94,794 | -3,340 (-3.40%) | 0.71% | $2 M | Nov 16, 2026 |
Show all 100: investors 26 to 100
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Vanguard Fiduciary Trust Co | 87,537 | +10 (+0.01%) | 0.65% | $2 M | Nov 13, 2026 |
| 27 | UBS Group AG | 87,107 | -58,709 (-40.26%) | 0.65% | $2 M | Nov 10, 2026 |
| 28 | Prudential Financial Inc | 84,245 | +72,935 (+644.87%) | 0.63% | $2 M | Nov 16, 2026 |
| 29 | Vanguard Portfolio Management LLC | 78,365 | +1,592 (+2.07%) | 0.58% | $2 M | Nov 13, 2026 |
| 30 | Envestnet Asset Management Inc | 71,362 | -17,393 (-19.60%) | 0.53% | $1 M | Nov 16, 2026 |
| 31 | Massachusetts Financial Services Co /ma/ | 68,653 | -3,105 (-4.33%) | 0.51% | $1 M | Nov 12, 2026 |
| 32 | Ironwood Investment Management LLC | 65,744 | +241 (+0.37%) | 0.49% | $1 M | Nov 12, 2026 |
| 33 | BNP Paribas Financial Markets | 58,118 | -5,835 (-9.12%) | 0.43% | $1 M | Nov 12, 2026 |
| 34 | FMR LLC | 57,619 | +4,639 (+8.76%) | 0.43% | $1 M | Nov 10, 2026 |
| 35 | Barclays PLC | 54,333 | +2,014 (+3.85%) | 0.41% | $1 M | Nov 6, 2026 |
| 36 | Diker Management LLC | 51,662 | -2,000 (-3.73%) | 0.39% | $1 M | Nov 16, 2026 |
| 37 | HSBC Holdings PLC | 51,628 | +1,523 (+3.04%) | 0.39% | $1 M | Nov 16, 2026 |
| 38 | Jpmorgan Chase & Co | 49,112 | -5,103 (-9.41%) | 0.37% | $1 M | Nov 12, 2026 |
| 39 | Ameriprise Financial Inc | 45,900 | -6,455 (-12.33%) | 0.34% | $1 M | Nov 16, 2026 |
| 40 | Palumbo Wealth Management LLC | 44,656 | +4,580 (+11.43%) | 0.33% | $1 M | Nov 13, 2026 |
| 41 | Indivisible Partners | 43,019 | -3,235 (-6.99%) | 0.32% | $1 M | Oct 26, 2026 |
| 42 | Advyzon Investment Management, LLC | 42,414 | -3,208 (-7.03%) | 0.32% | $1 M | Nov 16, 2026 |
| 43 | Lazard Asset Management LLC | 41,973 | New | 0.31% | $1 M | Nov 16, 2026 |
| 44 | Assenagon Asset Management S.A. | 40,376 | -85,656 (-67.96%) | 0.30% | $1 M | Oct 15, 2026 |
| 45 | Cerity Partners LLC | 40,083 | -579 (-1.42%) | 0.30% | $1 M | Nov 13, 2026 |
| 46 | Bank of New York Mellon Corp | 39,337 | +564 (+1.45%) | 0.29% | $1 M | Nov 5, 2026 |
| 47 | Bank Of America Corp /de/ | 37,298 | +12,750 (+51.94%) | 0.28% | $1 M | Nov 16, 2026 |
| 48 | Invesco Ltd. | 36,062 | +5,549 (+18.19%) | 0.27% | $1 M | Nov 12, 2026 |
| 49 | Corient Private Wealth LP | 34,020 | -1,395 (-3.94%) | 0.25% | $1 M | Nov 16, 2026 |
| 50 | Tudor Investment Corp Et Al | 33,683 | +10,846 (+47.49%) | 0.25% | $1 M | Nov 16, 2026 |
| 51 | Marshall Wace, LLP | 31,197 | +9,279 (+42.34%) | 0.23% | $1 M | Nov 13, 2026 |
| 52 | Man Group plc | 31,118 | -109,594 (-77.89%) | 0.23% | $1 M | Nov 16, 2026 |
| 53 | State Of Wisconsin Investment Board | 30,342 | -3,558 (-10.50%) | 0.23% | $1 M | Nov 16, 2026 |
| 54 | Strs Ohio | 29,700 | +10,500 (+54.69%) | 0.22% | $1 M | Oct 30, 2026 |
| 55 | Ieq Capital, LLC | 29,651 | -3,815 (-11.40%) | 0.22% | $1 M | Nov 10, 2026 |
| 56 | American Century Companies Inc | 29,470 | -74,089 (-71.54%) | 0.22% | $1 M | Nov 12, 2026 |
| 57 | Mercer Global Advisors Inc /adv | 29,118 | +3,833 (+15.16%) | 0.22% | $1 M | Nov 16, 2026 |
| 58 | Bridgeway Capital Management, LLC | 25,208 | +7,708 (+44.05%) | 0.19% | $0 M | Nov 16, 2026 |
| 59 | Quadrature Capital Ltd | 24,135 | New | 0.18% | $0 M | Nov 13, 2026 |
| 60 | R Squared Ltd | 24,019 | -3,046 (-11.25%) | 0.18% | $0 M | Nov 6, 2026 |
| 61 | Point72 Asset Management, L.P. | 23,139 | +624 (+2.77%) | 0.17% | $0 M | Nov 16, 2026 |
| 62 | Mariner, LLC | 23,024 | -2,932 (-11.30%) | 0.17% | $0 M | Nov 12, 2026 |
| 63 | Martingale Asset Management L P | 23,014 | +7,702 (+50.30%) | 0.17% | $0 M | Nov 12, 2026 |
| 64 | Gsa Capital Partners LLP | 22,148 | -4,035 (-15.41%) | 0.17% | $0 M | Nov 16, 2026 |
| 65 | Citadel Advisors LLC | 21,792 | New | 0.16% | $0 M | Nov 16, 2026 |
| 66 | Alliancebernstein L.P. | 20,850 | -1,060 (-4.84%) | 0.16% | $0 M | Nov 16, 2026 |
| 67 | Segall Bryant & Hamill, LLC | 19,877 | New | 0.15% | $0 M | Nov 16, 2026 |
| 68 | Blueprint Investment Partners LLC | 17,646 | New | 0.13% | $0 M | Oct 28, 2026 |
| 69 | Blueprint Financial Advisors LLC | 17,646 | New | 0.13% | $0 M | Oct 28, 2026 |
| 70 | Millennium Management LLC | 17,210 | +2,773 (+19.21%) | 0.13% | $0 M | Nov 16, 2026 |
| 71 | Empowered Funds, LLC | 17,208 | New | 0.13% | $0 M | Nov 13, 2026 |
| 72 | Northwest & Ethical Investments L.P. | 16,389 | New | 0.12% | $0 M | Nov 12, 2026 |
| 73 | Rhumbline Advisers | 15,611 | -733 (-4.48%) | 0.12% | $0 M | Nov 10, 2026 |
| 74 | Integrated Quantitative Investments LLC | 15,540 | -3,539 (-18.55%) | 0.12% | $0 M | Nov 13, 2026 |
| 75 | Bailard, Inc. | 15,526 | New | 0.12% | $0 M | Oct 13, 2026 |
| 76 | Wealth Enhancement Advisory Services, LLC | 15,476 | -101 (-0.65%) | 0.12% | $0 M | Oct 13, 2026 |
| 77 | Simplicity Wealth,LLC | 14,500 | New | 0.11% | $0 M | Oct 23, 2026 |
| 78 | Canada Pension Plan Investment Board | 13,000 | -9,000 (-40.91%) | 0.10% | $0 M | Nov 16, 2026 |
| 79 | Los Angeles Capital Management LLC | 12,900 | +12,800 (+12800.00%) | 0.10% | $0 M | Nov 12, 2026 |
| 80 | XTX Topco Ltd | 12,830 | -5,044 (-28.22%) | 0.10% | $0 M | Nov 16, 2026 |
| 81 | Noesis Capital Mangement Corp | 11,740 | -7,660 (-39.48%) | 0.09% | $0 M | Oct 26, 2026 |
| 82 | Squarepoint Ops LLC | 11,304 | -7,447 (-39.72%) | 0.08% | $0 M | Nov 9, 2026 |
| 83 | Kemnay Advisory Services Inc. | 10,450 | +2,492 (+31.31%) | 0.08% | $0 M | Nov 16, 2026 |
| 84 | Connor, Clark & Lunn Investment Management Ltd. | 10,389 | New | 0.08% | $0 M | Nov 10, 2026 |
| 85 | Russell Investments Group, Ltd. | 10,282 | +1,873 (+22.27%) | 0.08% | $0 M | Nov 6, 2026 |
| 86 | MetLife Investment Management, LLC | 7,122 | 0 (0.00%) | 0.05% | $0 M | Nov 16, 2026 |
| 87 | Arax Advisory Partners | 6,010 | +436 (+7.82%) | 0.04% | $0 M | Nov 12, 2026 |
| 88 | Vanguard Global Advisers, LLC | 5,816 | +1,497 (+34.66%) | 0.04% | $0 M | Nov 13, 2026 |
| 89 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 5,472 | +200 (+3.79%) | 0.04% | $0 M | Nov 16, 2026 |
| 90 | Citigroup Inc | 3,670 | -1,608 (-30.47%) | 0.03% | $0 M | Nov 4, 2026 |
| 91 | Versant Capital Management, Inc | 3,446 | -287 (-7.69%) | 0.03% | $0 M | Oct 2, 2026 |
| 92 | New York State Common Retirement Fund | 3,423 | 0 (0.00%) | 0.03% | $0 M | Nov 17, 2026 |
| 93 | Police & Firemen's Retirement System of New Jersey | 3,262 | 0 (0.00%) | 0.02% | $0 M | Nov 9, 2026 |
| 94 | Public Employees Retirement System Of Ohio | 2,910 | -16,065 (-84.66%) | 0.02% | $0 M | Nov 16, 2026 |
| 95 | Meeder Asset Management Inc | 2,736 | +240 (+9.62%) | 0.02% | $0 M | Nov 10, 2026 |
| 96 | Wells Fargo & Company/mn | 2,294 | -7,362 (-76.24%) | 0.02% | $0 M | Nov 16, 2026 |
| 97 | PNC Financial Services Group, Inc. | 1,557 | +66 (+4.43%) | 0.01% | $0 M | Nov 6, 2026 |
| 98 | Ameritas Investment Partners, Inc. | 1,202 | 0 (0.00%) | 0.01% | $0 M | Nov 13, 2026 |
| 99 | Allworth Financial LP | 1,102 | +111 (+11.20%) | 0.01% | $0 M | Nov 17, 2026 |
| 100 | Legal & General Group Plc | 1,081 | 0 (0.00%) | 0.01% | $0 M | Nov 16, 2026 |
Mutual funds holding Anika Therapeutics, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 397,824 | $6 M | 3.0% | <0.01% | −7.2% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 311,291 | $5 M | 2.3% | <0.01% | +1.8% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 123,749 | $2 M | 0.92% | <0.01% | +1.8% | Jul 31, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 162,458 | $2 M | 1.2% | <0.01% | −0.4% | Jun 30, 2026 |
| 🇺🇸 College Retirement Equities Fund - Total Global Stock AccountTIAA-CREF Investment Management, LLC | 142,287 | $2 M | 1.1% | <0.01% | +71% | Jun 30, 2026 |
| 🇺🇸 U.S. Small Cap Value PortfolioDimensional Fund Advisors LP | 86,697 | $2 M | 0.65% | <0.01% | +53% | Jul 31, 2026 |
| 🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors | 104,916 | $2 M | 0.78% | 0.01% | +0.2% | Jun 30, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Value ETFAmerican Century ETF Trust | 101,973 | $1 M | 0.76% | <0.01% | +6.0% | May 31, 2026 |
| 🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP | 61,098 | $1 M | 0.46% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Dimensional US Small Cap Value ETFDimensional Fund Advisors LP | 56,771 | $1 M | 0.42% | 0.01% | +38% | Jul 31, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 73,771 | $1 M | 0.55% | <0.01% | −4.4% | May 31, 2026 |
| 🇺🇸 Schwab U.S. Small-Cap ETFCharles Schwab Investment Management, Inc. | 66,746 | $1 M | 0.50% | <0.01% | −1.3% | May 31, 2026 |
| 🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP | 49,285 | $1 M | 0.37% | 0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc. | 64,319 | $1 M | 0.48% | <0.01% | +4.5% | May 31, 2026 |
| 🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP | 41,182 | $1 M | 0.31% | <0.01% | −6.2% | Jul 31, 2026 |
| 🇺🇸 MFS Blended Research Small Cap Equity FundMASSACHUSETTS FINANCIAL SERVICES COMPANY | 48,172 | $1 M | 0.36% | 0.21% | −3.7% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 38,472 | $1 M | 0.29% | 0.04% | +23% | Jun 30, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 27,027 | $1 M | 0.20% | <0.01% | +0.2% | Jul 31, 2026 |
| 🇺🇸 Multi-Manager Small Cap Equity Strategies FundColumbia Funds Series Trust I | 35,515 | $1 M | 0.27% | 0.04% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 26,302 | $0 M | 0.20% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust | 24,030 | $0 M | 0.18% | 0.01% | −11% | May 31, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 22,850 | $0 M | 0.17% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 NVIT Multi-Manager Small Company FundNATIONWIDE FUND ADVISORS | 22,292 | $0 M | 0.17% | 0.07% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 21,446 | $0 M | 0.16% | <0.01% | +6.9% | May 31, 2026 |
| 🇺🇸 NVIT Small Cap Value FundNATIONWIDE FUND ADVISORS | 20,885 | $0 M | 0.16% | 0.14% | −3.2% | Jun 30, 2026 |
| 🇺🇸 Invesco RAFI US 1500 Small-Mid ETFInvesco Capital Management LLC | 15,448 | $0 M | 0.12% | 0.01% | +3.7% | Jul 31, 2026 |
| 🇺🇸 VIP Disciplined Small Cap PortfolioFidelity Management & Research Company LLC | 18,236 | $0 M | 0.14% | 0.04% | +47% | Jun 30, 2026 |
| 🇺🇸 U.S. Core Equity 2 PortfolioDimensional Fund Advisors LP | 13,792 | $0 M | 0.10% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC | 17,500 | $0 M | 0.13% | 0.17% | no change | Jun 30, 2026 |
| 🇺🇸 U.S. Targeted Value PortfolioDimensional Fund Advisors LP | 12,107 | $0 M | 0.09% | <0.01% | −80% | Jul 31, 2026 |
| 🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC | 15,789 | $0 M | 0.12% | 0.01% | +4.5% | Jun 30, 2026 |
| 🇺🇸 U.S. Vector Equity PortfolioDimensional Fund Advisors LP | 11,894 | $0 M | 0.09% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 U.S. Core Equity 1 PortfolioDimensional Fund Advisors LP | 11,355 | $0 M | 0.08% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Small Cap Equity FundGuideStone Capital Management, LLC | 14,782 | $0 M | 0.11% | 0.02% | −40% | Jun 30, 2026 |
| 🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC | 11,088 | $0 M | 0.08% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Goldman Sachs ActiveBeta U.S. Small Cap Equity ETFGoldman Sachs Asset Management, L.P. | 13,535 | $0 M | 0.10% | 0.02% | +1.3% | May 31, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 10,042 | $0 M | 0.07% | <0.01% | −45% | Jul 31, 2026 |
| 🇺🇸 PGIM Quant Solutions Small-Cap Value FundPGIM INVESTMENTS LLC | 10,000 | $0 M | 0.07% | 0.04% | new | Jul 31, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 10,000 | $0 M | 0.07% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 12,430 | $0 M | 0.09% | <0.01% | +6.2% | Jun 30, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 11,614 | $0 M | 0.09% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC | 7,602 | $0 M | 0.06% | <0.01% | +12% | Jul 31, 2026 |
| 🇺🇸 Dimensional U.S. Targeted Value ETFDimensional Fund Advisors LP | 7,426 | $0 M | 0.06% | <0.01% | −74% | Jul 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc. | 9,661 | $0 M | 0.07% | 0.01% | +8.8% | May 31, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 9,395 | $0 M | 0.07% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Schwab U.S. Broad Market ETFCharles Schwab Investment Management, Inc. | 8,500 | $0 M | 0.06% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 8,165 | $0 M | 0.06% | <0.01% | −25% | May 31, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 7,980 | $0 M | 0.06% | <0.01% | +10% | Jun 30, 2026 |
| 🇺🇸 Dimensional U.S. Marketwide Value ETFDimensional Fund Advisors LP | 6,027 | $0 M | 0.04% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P. | 7,493 | $0 M | 0.06% | <0.01% | −11% | Jun 30, 2026 |
| 🇺🇸 U.S. Sustainability Core 1 PortfolioDimensional Fund Advisors LP | 5,680 | $0 M | 0.04% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 7,261 | $0 M | 0.05% | <0.01% | −24% | Jun 30, 2026 |
| 🇺🇸 JPMorgan Diversified Return U.S. Small Cap Equity ETFJ.P. Morgan Investment Management Inc. | 5,502 | $0 M | 0.04% | 0.02% | +15% | Jul 31, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 5,460 | $0 M | 0.04% | <0.01% | +0.9% | Jul 31, 2026 |
| 🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors | 6,693 | $0 M | 0.05% | <0.01% | −23% | Jun 30, 2026 |
| 🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC | 4,935 | $0 M | 0.04% | <0.01% | −4.3% | Jul 31, 2026 |
| 🇺🇸 iShares Russell 3000 ETFBlackRock Fund Advisors | 6,026 | $0 M | 0.04% | <0.01% | −0.8% | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 5,800 | $0 M | 0.04% | <0.01% | −13% | Jun 30, 2026 |
| 🇺🇸 Dimensional VA U.S. Targeted Value PortfolioDimensional Fund Advisors LP | 4,287 | $0 M | 0.03% | <0.01% | −16% | Jul 31, 2026 |
| 🇺🇸 Venerable US Small Cap FundVenerable Investment Advisers, LLC | 5,244 | $0 M | 0.04% | 0.05% | −2.9% | Jun 30, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC | 5,191 | $0 M | 0.04% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 5,047 | $0 M | 0.04% | <0.01% | +28% | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company | 5,068 | $0 M | 0.04% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 AQR Small Cap Multi-Style FundAQR CAPITAL MANAGEMENT, LLC | 4,683 | $0 M | 0.03% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 4,570 | $0 M | 0.03% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC | 4,117 | $0 M | 0.03% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC | 3,758 | $0 M | 0.03% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 3,621 | $0 M | 0.03% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 3,552 | $0 M | 0.03% | <0.01% | −20% | Jun 30, 2026 |
| 🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS | 2,660 | $0 M | 0.02% | <0.01% | +555% | Jul 31, 2026 |
| 🇺🇸 Avantis U.S. Equity ETFAmerican Century ETF Trust | 3,415 | $0 M | 0.03% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION | 3,070 | $0 M | 0.02% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Value FundAmerican Century ETF Trust | 2,971 | $0 M | 0.02% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Thrivent Moderately Aggressive Allocation PortfolioThrivent Financial for Lutherans | 2,953 | $0 M | 0.02% | <0.01% | +52% | Jun 30, 2026 |
| 🇺🇸 U.S. Social Core Equity 2 PortfolioDimensional Fund Advisors LP | 2,097 | $0 M | 0.02% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 AST Small-Cap Equity PortfolioAST Investment Services, Inc. | 2,680 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Thrivent Moderately Aggressive Allocation FundThrivent Asset Management LLC | 2,032 | $0 M | 0.02% | <0.01% | +52% | Jul 31, 2026 |
| 🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC | 2,005 | $0 M | 0.01% | <0.01% | −7.4% | Jul 31, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 2,601 | $0 M | 0.02% | 0.02% | +19% | Jun 30, 2026 |
| 🇺🇸 Spectrum FundMeeder Asset Management, Inc. | 2,496 | $0 M | 0.02% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Dimensional U.S. Equity Market ETFDimensional Fund Advisors LP | 1,888 | $0 M | 0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 1,887 | $0 M | 0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC | 2,483 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Thrivent Moderate Allocation PortfolioThrivent Financial for Lutherans | 2,447 | $0 M | 0.02% | <0.01% | +52% | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 2,320 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Thrivent Aggressive Allocation FundThrivent Asset Management LLC | 1,522 | $0 M | 0.01% | <0.01% | +51% | Jul 31, 2026 |
| 🇺🇸 Strategic Advisers U.S. Total Stock FundStrategic Advisers LLC | 1,992 | $0 M | 0.01% | <0.01% | −55% | May 31, 2026 |
| 🇺🇸 LVIP Dimensional U.S. Core Equity 1 FundLincoln Financial Investments Corporation | 1,937 | $0 M | 0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC | 1,467 | $0 M | 0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC | 1,919 | $0 M | 0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 1,455 | $0 M | 0.01% | <0.01% | −1.3% | Jul 31, 2026 |
| 🇺🇸 Dimensional US Core Equity Market ETFDimensional Fund Advisors LP | 1,436 | $0 M | 0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC | 1,889 | $0 M | 0.01% | <0.01% | +32% | Jun 30, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 1,826 | $0 M | 0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 SA U.S. Small Company FundFocus Advisor Solutions, LLC | 1,795 | $0 M | 0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 1,783 | $0 M | 0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 1,722 | $0 M | 0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 iShares Total U.S. Stock Market Index FundBlackRock Advisors, LLC | 1,304 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Small Cap Opportunities TrustJohn Hancock Variable Trust Advisers LLC | 1,585 | $0 M | 0.01% | 0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC | 1,500 | $0 M | 0.01% | <0.01% | no change | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 100 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Anika Therapeutics, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Gary P. FischettiDirector | Buy | +1,000 | $20.32 | $20 K | 54,015 | Form 4 |
| filed | Gary P. FischettiDirector | Buy | +1,000 | $20.75 | $21 K | 53,015 | Form 4 |
| filed | John B. Henneman IIIDirector | Grant or award | +10,402 | — | — | 65,273 | Form 4 |
| filed | Joseph H. CapperDirector | Grant or award | +10,402 | — | — | 30,805 | Form 4 |
| filed | Gary P. FischettiDirector | Grant or award | +10,402 | — | — | 52,015 | Form 4 |
| filed | Stephen RichardDirector | Grant or award | +10,402 | — | — | 58,273 | Form 4 |
| filed | Sheryl L. ConleyDirector | Grant or award | +10,402 | — | — | 52,970 | Form 4 |
| filed | Stephen D. GriffinPresident and CEO, Director | Option exercise | +12,840 | — | — | 49,742 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Anika Therapeutics, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
| Buybacks, quarter | Fiscal | Spent |
|---|---|---|
| Q3 2026 | Q3 2026 | $0M |
| Q2 2026 | Q2 2026 | $0.9M |
| Q1 2026 | Q1 2026 | $8.7M |
| Q4 2025 | Q4 2025 | $5.5M |
| Q3 2025 | Q3 2025 | $0M |
| Q2 2025 | Q2 2025 | $0M |
| Q1 2025 | Q1 2025 | $4M |
| Q4 2024 | Q4 2024 | $5.6M |
| Q3 2024 | Q3 2024 | $4M |
| Q2 2024 | Q2 2024 | $1.4M |
| Q1 2024 | Q1 2025 | $0M |
| Q4 2023 | Q4 2023 | $0M |
| Q3 2023 | Q3 2023 | $0M |
| Q4 2022 | Q4 2023 | $0M |
| Q3 2022 | Q3 2023 | $0M |
| Q4 2020 | Q4 2020 | $0M |
Fails to deliver
- : 55 shares at $19.95
- : 659 shares at $20.68
- : 223 shares at $21.42
- : 15 shares at $19.19
- : 13 shares at $19.28
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Anika Therapeutics, Inc. scorecard#
Passes 8 of the 22 checks that could be worked out: strongest in financial health (2 of 3), weakest in growth (1 of 6). Fiscal year 2025; market cap of Sep 30, 2026.
Valuation2 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median1.9×Price to book 1.9× against Biotechnology's median of 2.9×.
- ✓Price to sales below its peers' median2.2×Price to sales 2.2× against Biotechnology's median of 8.7×.
- ✗Free cash flow yield above 5%1.6%Free cash flow is 1.6% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth1 of 6
- ✗Revenue grew in the newest year-5.9%Revenue down 5.9% in fiscal 2025.
- ✗Revenue up more than 5% a year over three years-0.3%-0.3% a year over the three years to fiscal 2025.
- ✗Faster growth over three years than its peers' median-0.3%-0.3% a year against Biotechnology's median of 12.9% (181 companies).
- ✗Earnings per share grew in the newest year-0.76 vs -3.83Diluted EPS -0.76 in fiscal 2025 against -3.83 the year before (report's currency).
- ✓Net income higher than five years earlier-$11 M-$11 M in fiscal 2025 against -$24 M in 2020.
- ✗Revenue rose in at least four of the last five years2 of 5Revenue rose in 2 of the five years to fiscal 2025.
Profitability1 of 5
- ✗Profitable in the newest year-$11 MNet income -$11 M in fiscal 2025.
- ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2025.
- ✓Operating margin above its peers' median-9.8%-9.8% against Biotechnology's median of -60.5% (243 companies).
- ✗Return on equity above 15%-7.3%-7.3% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- ✗Operating margin wider than three years earlier-9.8%-9.8% in fiscal 2025 against 3.2% in 2022.
Financial health2 of 3
- ✓Short-term assets cover short-term liabilities4.7×Current ratio 4.72 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years2 of 3Positive in 2 of the three years to fiscal 2025.
- ✓Altman Z-score outside the distress zone4.79Z-score 4.79 (safe zone) for fiscal 2025.
Shareholder returns2 of 3
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✓Share count up no more than 2% in a year-2.6%Diluted shares down 2.6% in fiscal 2025.
- ✓Dividends and buybacks above 3% of the market value3.5%Dividends and buybacks were 3.5% of the market value.
- ✗Free cash flow covers dividends and buybacks$4 MFree cash flow $4 M against $9 M paid out in fiscal 2025.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Anika Therapeutics, Inc.'s statements, beside the median of Biotechnology.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -9.8% | -60.5% | |
| Net margin | -9.6% | -68.9% | |
| Return on equity | -7.3% | -61.0% | |
| Revenue growth, 3 years a year | -0.3% | 12.9% | |
| Revenue growth | -5.9% | 15.8% | |
| Free cash flow margin | 3.9% | -61.5% |
5of 8on the Piotroski tests of financial strength
- Revenue fell 5.9% against the year before.
- Net loss of $11 million, the 4th loss-making year in a row.
- The share count fell 2.6% in the year (buybacks).
Anika Therapeutics, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 113−5.9%100% | 120−0.7%100% | 121r167+6.1%100% | 114r156−23.0%100% | 148+13.3%100% | 130+13.8%100% | 115+8.6%100% | 106−6.9%100% | 113+9.7%100% | 103—100% | |
| Cost of revenue | 49+11.6%43.4% | 44+14.8%36.6% | 38r64−5.8%31.7% | 41r63−37.4%35.7% | 65+5.6%43.9% | 61+114%47.1% | 29−8.1%25.1% | 31+14.3%29.6% | 27+13.9%24.1% | 24—23.2% | |
| Gross profit | 64−16.0%56.6% | 76−7.9%63.4% | 83r103+12.7%68.3% | 73r94−11.7%64.3% | 83+20.2%56.1% | 69−19.6%52.9% | 86+15.6%74.9% | 74—70.4% | — | — | |
| Research and development | 26+0.9%22.8% | 26+17.4%21.3% | 22r33+18.8%18.0% | 18r28−33.0%16.1% | 27+16.6%18.5% | 23+40.6%18.0% | 17−8.4%14.5% | 18−3.2%17.2% | 19+75.1%16.6% | 11—10.4% | |
| Selling, general and administrative | 49−11.6%43.5% | 56−7.3%46.3% | 60r96+17.0%49.6% | 51r85−30.9%45.0% | 74+23.4%50.1% | 60+71.9%46.0% | 35+1.8%30.5% | 34+59.4%32.5% | 22+19.6%19.0% | 18—17.4% | |
| Total costs and expenses | 75−7.7%66.4% | 81−0.7%67.6% | 82r191+17.5%67.6% | 70r113−13.4%61.1% | 80−17.5%54.4% | 97+88.6%74.6% | 52r80−1.7%45.0% | 53r84−22.4%49.8% | 68+28.3%59.7% | 53—51.0% | |
| Operating income | −11—−9.8% | −5.1−704%−4.3% | 0.8r−88−77.0%0.7% | 3.7r−19+40.3%3.2% | 2.6—1.8% | −28−183%−21.7% | 34+57.5%29.9% | 22−52.4%20.6% | 46−9.6%40.3% | 51—49.0% | |
| Income before tax | −9.3—−8.2% | −2.8−188%−2.3% | 3.2r−85−27.0%2.6% | 4.3r−19+78.2%3.8% | 2.4—1.6% | −29−179%−21.9% | 36+55.6%31.5% | 23−49.8%22.0% | 46−9.2%40.7% | 51—49.2% | |
| Income tax | 0.7−88.9%0.6% | 6.1−8.1%5.1% | 6.6r−2.7+210%5.5% | 2.1r−3.9—1.9% | −1.7—−1.2% | −4.6−152%−3.6% | 8.9+99.1%7.8% | 4.5−68.8%4.2% | 14−21.5%12.7% | 18—17.7% | |
| Income from continuing operations | −10.0—−8.8% | −8.8—−7.4% | −3.4−256%−2.8% | 2.2—1.9% | — | — | — | — | — | — | |
| Income from discontinued operations | −0.9—−0.8% | −48—−39.7% | −79—−65.6% | −17—−15.0% | — | — | — | — | — | — | |
| Net income attributable to shareholders | −11—−9.6% | −56—−47.0% | −83—−68.4% | −15−459%−13.1% | 4.1—2.8% | −24−188%−18.4% | 27+45.2%23.7% | 19−41.2%17.7% | 32−2.2%28.1% | 33—31.5% | |
| Earnings per share, basic | -0.76—— | -3.83—— | -5.64—— | -1.02−452%— | 0.29—— | -1.69−188%— | 1.93+48.5%— | 1.30−40.4%— | 2.18−1.8%— | 2.22—— | |
| Earnings per share, diluted | -0.76—— | -3.83—— | -5.64—— | -1.02−464%— | 0.28—— | -1.69−189%— | 1.89+48.8%— | 1.27−39.8%— | 2.11−1.9%— | 2.15—— | |
| Shares, weighted average (basic) | 14−2.6%— | 15+0.4%— | 15+0.7%— | 15+1.1%— | 14+1.3%— | 14r14+0.7%— | 14r14−2.2%— | 14r14−0.9%— | 15−0.7%— | 15—— | |
| Shares, weighted average (diluted) | 14−2.6%— | 15+0.4%— | 15−0.9%— | 15r15+1.0%— | 15+2.9%— | 14r14−1.1%— | 14r14−2.1%— | 15r15−2.5%— | 15−0.3%— | 15—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 57+3.3%30.2% | 56−19.1%27.4% | 69r73−20.4%25.4% | 86−8.5%24.7% | 94−1.5%27.2% | 96−39.1%26.2% | 157+76.8%47.6% | 89−33.2%31.9% | 133+27.8%47.2% | 104—43.4% | |
| Short-term investments | 24+0.4%12.5% | 24−10.5%11.6% | 26r36−23.9%9.7% | 35+16.0%9.9% | 30r0+1093%8.6% | 2.5−90.9%0.7% | 27−60.7%8.3% | 70+192%25.1% | 24+17.1%8.5% | 21—8.5% | |
| Receivables | 24+0.4%12.5% | 24−10.5%11.6% | 26r36−23.9%9.7% | 35+16.0%9.9% | 30+23.8%8.6% | 24+4.4%6.6% | 23+11.1%7.0% | 21−12.8%7.4% | 24−13.7%8.4% | 28—11.5% | |
| Inventory | 19−21.1%9.9% | 24−2.5%11.7% | 24r46−38.6%9.0% | 40+10.4%11.4% | 36−22.1%10.4% | 46+110%12.6% | 22+3.3%6.7% | 21−3.3%7.6% | 22+37.9%7.8% | 16—6.7% | |
| Other current assets | 3.4−38.1%1.8% | 5.5−26.5%2.7% | 7.5r8.1−15.3%2.8% | 8.8+6.5%2.5% | 8.3−5.3%2.4% | 8.8+104%2.4% | 4.3+131%1.3% | 1.9−42.3%0.7% | 3.2+53.1%1.1% | 2.1—0.9% | |
| Current assets | 103−9.1%54.3% | 114−30.4%56.1% | 163−3.7%60.3% | 170+0.6%48.6% | 169−5.0%48.5% | 177−24.3%48.5% | 234+15.5%70.8% | 203−1.6%72.7% | 206+21.1%73.0% | 170—70.9% | |
| Property, plant and equipment | 40+3.4%21.2% | 39+4.1%19.2% | 37r46−22.4%13.8% | 48+1.4%13.8% | 48−5.9%13.7% | 51−0.3%13.8% | 51−6.2%15.4% | 54−3.7%19.4% | 56+7.4%19.9% | 52—21.8% | |
| Right-of-use (leased) assets | 26+1.0%13.6% | 26−6.8%12.7% | 28r29−10.2%10.2% | 31+46.5%8.8% | 21−7.3%6.0% | 23−1.1%6.2% | 23—6.9% | — | — | — | |
| Goodwill | 8.1+13.0%4.2% | 7.1−5.9%3.5% | 7.6+3.2%2.8% | 7.3−5.7%2.1% | 7.8−7.5%2.2% | 8.4+9.3%2.3% | 7.7−2.0%2.3% | 7.9−4.5%2.8% | 8.2+13.9%2.9% | 7.2—3.0% | |
| Other intangible assets | 1.7−33.7%0.9% | 2.5−3.3%1.2% | 2.6r4.6−96.5%1.0% | 75−9.4%21.4% | 82−9.6%23.7% | 91+1102%24.9% | 7.6−17.5%2.3% | 9.2−13.6%3.3% | 11+4.0%3.8% | 10—4.3% | |
| Total assets | 190−6.2%100% | 203−25.1%100% | 271−22.5%100% | 349+0.5%100% | 348−4.9%100% | 366+10.6%100% | 331+18.5%100% | 279−1.3%100% | 283+17.6%100% | 240—100% | |
| Accounts payable | 6.0+7.5%3.2% | 5.6−9.3%2.8% | 6.2r9.9−31.7%2.3% | 9.1+18.9%2.6% | 7.6−15.0%2.2% | 9.0+134%2.5% | 3.8+21.9%1.2% | 3.1−53.4%1.1% | 6.7+193%2.4% | 2.3—1.0% | |
| Current liabilities | 22−6.0%11.5% | 23−25.0%11.5% | 31+11.3%11.5% | 28−6.3%8.0% | 30−19.2%8.6% | 37+126%10.1% | 16+44.2%4.9% | 11−13.6%4.0% | 13+48.6%4.6% | 8.8—3.7% | |
| Long-term debt | — | — | — | — | — | — | 0—0.0% | — | — | — | |
| Lease liabilities (non-current) | 24+0.8%12.7% | 24−7.3%11.8% | 26r27−10.1%9.6% | 29+49.8%8.3% | 19−7.8%5.5% | 21−2.3%5.7% | 21—6.5% | — | — | — | |
| Retained earnings | 61−15.2%31.9% | 72−44.0%35.3% | 128−39.2%47.3% | 211−6.6%60.4% | 226+1.9%64.9% | 221−9.8%60.6% | 245+12.5%74.2% | 218+9.4%78.2% | 200+18.6%70.6% | 168—70.0% | |
| Shareholders' equity | 143−6.8%75.4% | 154−27.5%76.0% | 212−25.7%78.4% | 286−0.5%81.8% | 287+5.4%82.6% | 272−5.5%74.5% | 288+9.4%87.2% | 264+0.0%94.5% | 263+18.3%93.2% | 223—92.7% | |
| Total liabilities and equity | 190−6.2%100% | 203−25.1%100% | 271−22.5%100% | 349+0.5%100% | 348−4.9%100% | 366+10.6%100% | 331+18.5%100% | 279−1.3%100% | 283+17.6%100% | 240—100% | |
| Shares outstanding | 14−3.7%— | 14−1.7%— | 15+0.2%— | 15+1.3%— | 14+0.8%— | 14+0.1%— | 14+0.7%— | 14−3.3%— | 15+0.4%— | 15r15—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 5.4−22.0%4.8% | 6.9+7.0%5.7% | 6.4−4.0%5.3% | 6.7+3.5%5.9% | 6.5+6.5%4.4% | 6.1r13+22.7%4.7% | 5.0r6.0−16.1%4.3% | 5.9+37.8%5.6% | 4.3+14.9%3.8% | 3.7—3.6% | |
| Share-based compensation | 10−23.2%8.9% | 13−13.9%11.0% | 15+6.5%12.6% | 14+29.1%12.6% | 11+106%7.5% | 5.4−11.5%4.1% | 6.1−44.9%5.3% | 11+90.2%10.5% | 5.8+71.2%5.1% | 3.4—3.3% | |
| Cash from operating activities | 11+107%9.9% | 5.4—4.5% | −1.8−141%−1.5% | 4.4−47.5%3.9% | 8.4−35.7%5.7% | 13−64.7%10.0% | 37+6.0%32.3% | 35−14.4%33.1% | 41+66.9%36.0% | 24r24—23.6% | |
| Capital expenditure | −6.8—−6.1% | −7.7—−6.4% | −5.4—−4.5% | −7.5—−6.6% | −5.1—−3.5% | −1.6—−1.2% | −2.8—−2.5% | −4.7—−4.4% | −9.0—−7.9% | −14—−13.6% | |
| Intangible assets bought | 0—0.0% | −0.6—−0.5% | 0—0.0% | 0—0.0% | — | — | — | — | — | — | |
| Acquisitions, net of cash acquired | — | — | 0—0.0% | 0—0.0% | −0.5—−0.3% | −95—−72.5% | 0—0.0% | 0—0.0% | — | — | |
| Cash from investing activities | −0.4—−0.4% | −8.3—−7.0% | −5.4—−4.5% | −7.5—−6.6% | −3.1—−2.1% | −71−280%−54.6% | 40—34.6% | −50—−47.6% | −12—−11.0% | −6.8—−6.5% | |
| Debt issued | — | — | — | 0—0.0% | 0−100%0.0% | 50—38.3% | 0—0.0% | 0—0.0% | — | — | |
| Debt repaid | — | — | — | 0—0.0% | 0—0.0% | −50—−38.6% | 0—0.0% | 0—0.0% | — | — | |
| Shares bought back | −9.5—−8.4% | −11—−9.1% | −5.0—−4.1% | 0—0.0% | 0—0.0% | 0—0.0% | −30—−26.2% | −30—−28.4% | — | −25—−24.2% | |
| Cash from financing activities | −11—−9.4% | −13—−10.6% | −6.3—−5.2% | −4.9—−4.3% | −6.8—−4.6% | −3.8—−2.9% | −8.1—−7.1% | −29−9305%−27.4% | 0.3—0.3% | −24r−23—−23.2% | |
| Exchange-rate effect on cash | — | — | — | — | — | — | −0.1−559%−0.1% | 0.0−91.7%0.0% | 0.3—0.3% | −0.1—−0.1% | |
| Change in cash | 0.3—0.3% | −16—−13.1% | −13—−11.1% | −8.1—−7.1% | −1.4—−1.0% | −62−190%−47.3% | 68—59.7% | −44−252%−41.9% | 29—25.6% | −6.4—−6.2% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K/A | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 123+9.4%100% | 31+10.0%100% | 33+15.6%100% | 30+13.2%100% | 31*+0.0%100% | 28−5.9%100% | 28−8.2%100% | 26−9.8%100% | 31*—100% | 30r39—100% | 31r42—100% | 29r41—100% | — | |
| Cost of revenue | 45−11.5%36.6% | 12−3.9%38.4% | 11−18.0%34.9% | 11−7.6%35.8% | 11*−15.1%37.4% | 12+20.5%44.0% | 14+35.4%49.1% | 11+14.3%43.9% | 13*—44.0% | 10r37—34.3% | 10r15—33.3% | 10r16—34.6% | — | |
| Gross profit | 78+26.7%63.4% | 19+20.9%61.6% | 21+47.9%65.1% | 19+29.4%64.2% | 19*+12.0%62.6% | 16−19.7%56.0% | 14−29.9%50.9% | 15−22.6%56.1% | 17r23*+197%56.0% | 19r1.4—65.7% | 20r27—66.7% | 19r25—65.4% | 5.8r26*—— | |
| Research and development | 28+10.0%23.0% | 7.9+13.7%25.8% | 7.3+16.3%22.5% | 6.7+10.8%22.7% | 6.5*−0.8%21.1% | 6.9+16.8%25.0% | 6.3−5.5%22.4% | 6.1−5.5%23.2% | 6.5r2.7*—21.3% | 5.9r7.2—20.1% | 6.7r7.4—21.7% | 6.4r8.2—22.1% | — | |
| Selling, general and administrative | 52+8.5%42.5% | 12−1.8%38.1% | 11−10.5%33.6% | 18+37.7%60.0% | 12*+6.7%39.5% | 12−12.3%42.7% | 12−21.7%43.3% | 13−14.4%49.3% | 11*—37.0% | 14r19—45.8% | 16r20—50.8% | 15r22—51.9% | — | |
| Total costs and expenses | 81+9.0%65.5% | 20+3.9%63.9% | 18−1.4%56.1% | 24+29.1%82.7% | 19*+3.9%60.5% | 19−3.4%67.6% | 19−16.8%65.7% | 19−11.7%72.5% | 18*—58.3% | 19r29—65.9% | 22r27—72.6% | 21r30—74.0% | — | |
| Operating income | −2.6—−2.1% | −0.7—−2.3% | 3.0—9.1% | −5.5—−18.5% | 0.6*—2.1% | −3.2—−11.6% | −4.2—−14.8% | −4.3—−16.4% | −0.7r28*−103%−2.3% | −0.1r−28—−0.3% | −1.8r0.2—−5.9% | −2.5r−5.1—−8.6% | 25r−64*—— | |
| Income before tax | −1.0—−0.8% | −0.3—−1.1% | 3.4—10.4% | −4.8—−16.3% | 0.8*+1859%2.5% | −2.2−788%−8.0% | −4.0—−14.1% | −3.9—−14.8% | 0.0r29*−99.8%0.1% | 0.3r−28—1.1% | −1.2r0.8—−4.0% | −1.9r−4.5—−6.6% | 25r−63*—— | |
| Income tax | −0.7−118%−0.6% | −0.0−101%−0.0% | 0.1−89.6%0.2% | 0.2+164%0.8% | −1.0*−141%−3.4% | 0.9−56.7%3.4% | 0.7−48.6%2.4% | 0.1+107%0.3% | 2.5r2.9*−72.1%8.3% | 2.2r2.3—7.3% | 1.3r0.8—4.3% | 0.0—0.1% | 9.1r−0.2*—— | |
| Income from continuing operations | −0.3—−0.2% | −0.3—−1.0% | 3.3—10.1% | −5.1—−17.1% | 1.8*—5.9% | −3.2—−11.4% | −4.6—−16.5% | −4.0—−15.1% | −2.5*—−8.1% | −1.8—−6.2% | −2.5—−8.3% | −2.0—−6.7% | — | |
| Income from discontinued operations | −1.5—−1.2% | 0−100%0.0% | 0−100%0.0% | 0—0.0% | −1.5r−1.5*—−4.9% | 0.8r0.8—3.0% | 0.7−72.4%2.4% | −0.9—−3.5% | −19*—−63.3% | −28—−95.0% | 2.5—8.0% | −2.6—−8.8% | — | |
| Net income attributable to shareholders | −1.8—−1.4% | −0.3—−1.0% | 3.3—10.1% | −5.1—−17.1% | 0.3*—1.0% | −2.3—−8.4% | −4.0—−14.1% | −4.9—−18.6% | −22*—−71.4% | −30—−101% | −0.1—−0.3% | −4.5—−15.6% | −63*—— | |
| Earnings per share, basic | — | -0.02—— | 0.25—— | -0.37—— | — | -0.16—— | -0.28—— | -0.34—— | — | -2.03—— | -0.01—— | -0.31—— | — | |
| Earnings per share, diluted | — | -0.02—— | 0.24—— | -0.37—— | — | -0.16—— | -0.28—— | -0.34—— | — | -2.03—— | 0.00r-0.01—— | -0.31—— | — | |
| Shares, weighted average (basic) | 13−7.2%— | 13−7.2%— | 13−7.2%— | 14−5.4%— | — | 14−2.4%— | 14−3.2%— | 14−2.7%— | — | 15—— | 15—— | 15—— | — | |
| Shares, weighted average (diluted) | 13−7.2%— | 13−7.2%— | 14−5.5%— | 14−5.4%— | — | 14−2.4%— | 15−2.3%— | 14−2.7%— | — | 15—— | 15r15—— | 15—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 45—23.7% | 45−22.5%23.7% | 38−27.8%20.9% | 41−23.1%22.9% | 57+3.3%30.2% | 58−7.0%30.6% | 53−15.4%28.3% | 53−22.2%28.0% | 56−19.1%27.4% | 62—27.0% | 63—23.9% | 69—26.0% | 69r73—25.4% | |
| Short-term investments | — | — | — | 26+17.2%14.4% | 24+0.4%12.5% | 22−21.8%11.7% | 24−29.1%12.8% | 22−31.5%11.5% | 24−10.5%11.6% | 28—12.3% | 34—12.9% | 32—12.2% | 26r36—9.7% | |
| Receivables | 24—12.8% | 24+9.3%12.8% | 29+21.3%15.8% | 26+17.2%14.4% | 24+0.4%12.5% | 22−21.8%11.7% | 24−29.1%12.8% | 22−31.5%11.5% | 24−10.5%11.6% | 28—12.3% | 34—12.9% | 32—12.2% | 26r36—9.7% | |
| Inventory | 30—16.0% | 30+86.4%16.0% | 29+68.8%15.6% | 23+7.0%12.7% | 19−21.1%9.9% | 16−58.9%8.6% | 17−67.1%9.0% | 21−56.8%11.2% | 24−2.5%11.7% | 40—17.1% | 51—19.6% | 49—18.7% | 24r46—9.0% | |
| Other current assets | 3.5—1.8% | 3.5−32.1%1.8% | 3.2−40.2%1.7% | 3.9−32.3%2.2% | 3.4−38.1%1.8% | 5.1−10.8%2.7% | 5.3−24.0%2.8% | 5.8−34.3%3.1% | 5.5−26.5%2.7% | 5.8—2.5% | 6.9—2.6% | 8.8—3.4% | 7.5r8.1—2.8% | |
| Current assets | 103—54.3% | 103+1.4%54.3% | 99−0.1%54.1% | 94−8.7%52.2% | 103−9.1%54.3% | 102−25.4%53.6% | 99−35.9%52.9% | 103−35.5%53.8% | 114−30.4%56.1% | 136—58.8% | 155—59.0% | 159—60.3% | 163—60.3% | |
| Property, plant and equipment | 41—21.5% | 41+0.1%21.5% | 40−1.4%21.9% | 40−1.8%22.1% | 40+3.4%21.2% | 41−8.7%21.5% | 41r41−14.7%21.7% | 40−12.2%21.2% | 39+4.1%19.2% | 45—19.3% | 48—18.2% | 46—17.5% | 37r46—13.8% | |
| Right-of-use (leased) assets | 26—13.6% | 26+6.4%13.6% | 25+0.9%13.6% | 25+1.0%14.2% | 26+1.0%13.6% | 24−11.0%12.8% | 25−11.0%13.2% | 25−10.6%13.2% | 26−6.8%12.7% | 27—11.8% | 28—10.6% | 28—10.7% | 28r29—10.2% | |
| Goodwill | 7.8—4.1% | 7.8−3.4%4.1% | 7.8−2.9%4.3% | 7.9+6.3%4.4% | 8.1+13.0%4.2% | 8.1+5.2%4.2% | 8.1+9.6%4.3% | 7.4+0.3%3.9% | 7.1−5.9%3.5% | 7.7—3.3% | 7.4—2.8% | 7.4—2.8% | 7.6—2.8% | |
| Other intangible assets | 1.7—0.9% | 1.70.0%0.9% | 1.7−0.7%0.9% | 1.7−27.7%0.9% | 1.7−33.7%0.9% | 1.7−46.4%0.9% | 1.7−58.2%0.9% | 2.3−46.9%1.2% | 2.5−3.3%1.2% | 3.1—1.3% | 4.0—1.5% | 4.3—1.6% | 2.6r4.6—1.0% | |
| Total assets | 190—100% | 190+0.1%100% | 183−2.2%100% | 179−5.9%100% | 190−6.2%100% | 189−18.1%100% | 188−28.5%100% | 191−27.7%100% | 203−25.1%100% | 231—100% | 263—100% | 264—100% | 271—100% | |
| Accounts payable | 6.0—3.2% | 6.0+27.5%3.2% | 6.2+30.7%3.4% | 6.3+20.1%3.5% | 6.0+7.5%3.2% | 4.7−30.5%2.5% | 4.8−52.3%2.5% | 5.3−47.3%2.8% | 5.6−9.3%2.8% | 6.8—2.9% | 10.0—3.8% | 10—3.8% | 6.2r9.9—2.3% | |
| Current liabilities | 27—14.1% | 27+40.0%14.1% | 22+37.7%12.1% | 21+17.1%11.7% | 22−6.0%11.5% | 19−25.1%10.1% | 16−38.4%8.6% | 18−37.1%9.4% | 23−25.0%11.5% | 25—11.0% | 26—9.9% | 28—10.8% | 31—11.5% | |
| Lease liabilities (non-current) | 25—13.0% | 25+7.8%13.0% | 23+0.6%12.7% | 24+1.0%13.3% | 24+0.8%12.7% | 23−9.7%12.0% | 23−10.1%12.3% | 24−10.6%12.4% | 24−7.3%11.8% | 25—10.9% | 26—9.8% | 26—10.0% | 26r27—9.6% | |
| Retained earnings | 59—31.0% | 59−2.9%31.0% | 59−6.0%32.2% | 56−16.6%31.1% | 61−15.2%31.9% | 60−35.3%31.9% | 63−49.1%33.5% | 67−45.9%35.0% | 72−44.0%35.3% | 94—40.4% | 123—47.0% | 124—46.8% | 128—47.3% | |
| Shareholders' equity | 138—72.6% | 138−6.3%72.6% | 137−7.0%74.8% | 134−9.8%74.6% | 143−6.8%75.4% | 147−18.4%77.5% | 148−29.8%78.7% | 148−28.8%77.9% | 154−27.5%76.0% | 180—77.7% | 210—80.1% | 209—79.1% | 212—78.4% | |
| Total liabilities and equity | 190—100% | 190+0.1%100% | 183−2.2%100% | 179−5.9%100% | 190−6.2%100% | 189−18.1%100% | 188−28.5%100% | 191−27.7%100% | 203−25.1%100% | 231—100% | 263—100% | 264—100% | 271—100% | |
| Shares outstanding | 13—— | 13−7.1%— | 13−7.2%— | 13−6.8%— | 14−3.7%— | 14−1.9%— | 14−2.8%— | 14−3.3%— | 14−1.7%— | 15—— | 15—— | 15—— | 15—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 5.7+1.0%4.6% | 1.4*+3.5%4.7% | 1.5*+17.6%4.6% | 1.4+1.7%4.8% | 1.3*−15.5%4.3% | 1.4*−25.2%5.0% | 1.3*−26.0%4.5% | 1.4−20.2%5.3% | 1.6*−4.2%5.1% | 1.9*—6.3% | 1.7*—5.6% | 1.7—6.0% | 1.6*—— | |
| Share-based compensation | 15+53.6%12.3% | 4.2+91.6%13.9% | 1.8−28.1%5.6% | 6.6+132%22.4% | 2.5*+9.0%8.0% | 2.2−34.7%8.0% | 2.5r2.5−18.3%9.0% | 2.9−20.3%10.9% | 2.3*−40.9%7.4% | 3.4—11.5% | 3.1r3.9—10.1% | 3.6—12.4% | 3.8*—— | |
| Cash from operating activities | 7.5−8.0%6.1% | 8.4*+21.9%27.4% | −0.7*—−2.1% | −4.8—−16.4% | 4.6*+193%15.1% | 6.9*+37.0%24.7% | −0.2*—−0.7% | −0.1—−0.5% | 1.6*−56.5%5.2% | 5.0*—17.0% | −1.1*—−3.5% | −0.1—−0.4% | 3.6*—— | |
| Capital expenditure | −5.2—−4.2% | −1.7*—−5.4% | −1.4*—−4.4% | −1.4—−4.8% | −0.6*—−2.1% | −1.9*—−6.8% | −1.5*—−5.2% | −2.8—−10.8% | −1.3*—−4.3% | −1.2*—−4.1% | −3.4*—−11.1% | −1.8—−6.2% | −1.8*—— | |
| Intangible assets bought | — | — | — | — | 0*—0.0% | — | — | — | 0*—0.0% | — | — | — | 0*—— | |
| Cash from investing activities | −4.1—−3.3% | −1.8*—−5.7% | −1.3*—−3.9% | −1.2−174%−4.2% | 0.2*—0.6% | −1.7*—−6.2% | −0.5*—−1.9% | 1.7—6.4% | −1.3*—−4.3% | −1.8*—−6.1% | −3.4*—−11.1% | −1.8—−6.2% | −1.8*—— | |
| Shares bought back | −15—−12.2% | 0*—0.0% | −0.9*—−2.6% | −8.7—−29.3% | −5.5*—−18.0% | 0*—0.0% | 0*—0.0% | −4.0—−15.2% | −5.6*—−18.2% | −4.0*—−13.4% | −1.4*—−4.5% | 0—0.0% | 0*—— | |
| Cash from financing activities | −16—−13.2% | −0.0*—−0.1% | −0.7*−492%−2.1% | −10—−34.9% | −5.3*—−17.2% | −0.0*—−0.0% | 0.2*—0.6% | −5.4—−20.8% | −5.4*−1665%−17.5% | −4.0*—−13.5% | −1.1*—−3.6% | −2.3—−7.8% | 0.3*—— | |
| Change in cash | −13—−10.6% | 6.5*+35.7%21.4% | −2.6*—−8.0% | −16—−55.6% | −0.5*—−1.7% | 4.8*—17.3% | −0.2*—−0.7% | −3.8—−14.5% | −5.2*−335%−17.0% | −0.5*—−1.5% | −5.8*—−18.9% | −4.2—−14.6% | 2.2*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Anika Therapeutics, Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- OEM Channel$64 M57%-17%
- Commercial Channel$48 M43%+15%
Countries and regions
- 🇺🇸 USA$70 M62%-15%
- Europe$22 M20%+14%
- Other Location$21 M18%+14%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Executive pay at Anika Therapeutics, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Stephen D. Griffin | $4.9 M | $2.1 M | $1.3 M | $21 (peers $120) |
| 2024Stephen D. Griffin | $5.1 M | $2.5 M | $1.8 M | $36 (peers $91) |
| 2023Stephen D. Griffin | $4.5 M | $1.9 M | $1.4 M | $50 (peers $92) |
| 2022Stephen D. Griffin | $5.9 M | $3.6 M | $1.7 M | $65 (peers $89) |
| 2021Stephen D. Griffin | $4.2 M | $1.8 M | $1.2 M | $79 (peers $99) |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Anika Therapeutics, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Acquisition or sale completed 2 · Directors and officers 9 · Material agreement 2 · New debt 1 · Shareholder vote 3 · Results announced 13
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreementNew debt | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Directors and officersResults announced | 8-K | |
| Directors and officersResults announced | 8-K | |
| Directors and officersResults announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Acquisition or sale completed | 8-K | |
| Acquisition or sale completed | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Directors and officersMaterial agreement | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 6, 2026
Lobbying by Anika Therapeutics, Inc.#
$0 spent on lobbying the US Congress and federal agencies in 2020.
Lobbying firms hired in 2020
King & Spalding LLP
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2026 (so far) | $30 K | — | 1 |
| 2020 | $0 | — | 3 |
| 2019 | $0 | — | 4 |
| 2018 | $0 | — | 4 |
Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Anika Therapeutics, Inc.” and “Anika Therapeutics Inc”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero
H-1B hiring at Anika Therapeutics, Inc.#
2 labor condition applications certified in fiscal 2026 for 2 positions, at a median wage of $124 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Process Automation EngineerMechatronics Engineers | 1 | $113 K |
| Senior Process EngineerManufacturing Engineers | 1 | $134 K |
Where: Bedford, MA 2
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2026 | 2 | 2 | $124 K | 2 |
| FY2025 | 3 | 3 | $131 K | 3 |
| FY2024 | 3 | 3 | $111 K | 3 |
| FY2023 | 2 | 2 | $119 K | 2 |
| FY2022 | 1 | 1 | $102 K | 1 |
| FY2021 | 2 | 2 | $155 K | 4 |
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Anika Therapeutics, Inc.
Product recalls by Anika Therapeutics, Inc.#
1 recalls since 2015, 1,711 units in the notices that give a number. Medical devices (FDA): 1.
| Date | What and why | Units | Notice |
|---|---|---|---|
| Hyalomatrix, Product nos. 651105, 651103, 651104, and 651301 Product Usage: Hyalomatrix is a bi-layered, sterile, flexible, and comfortable wound dressing that acts as an advanced wound care device. It is comprised of a non-woven pad entirely composed of HY AFF 11, a benzyl ester of hyaluronic acid, and a semipermeable silicone…Hyalomatrix products are susceptible to degradation as a result of the decomposition of PVC in the packaging material during sterilization, which resulted in degradation of the film. Over the long term it is possible that product integrity may be compromised.Medical devicesClass II | 1,711 | Z-2423-2018 |
Source: NHTSA, CPSC and FDA recall notices. Recalls filed under a subsidiary with a different name may be missing. The number of recalls says nothing about their seriousness
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2012 | · | · | · | · | · | · | · | · | · | · | · | 12 | 12 |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| 12 people | Restructuring planSEC 8-K | “The plan adopted includes a reduction-in-force of 12 people and provides for severance payments, and the disposal of related supplies, equipment, and other assets.” | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How Anika Therapeutics, Inc. compares in Biotechnology
- Market cap$267 M · higher than 49% of 726
- Revenue$113 M · higher than 70% of 647
- Net margin-1.4% · higher than 70% of 408
- Revenue growth-5.9% · higher than 37% of 438
- Price / sales2.2× · lower than 83% of 339
- Price / book1.9× · lower than 60% of 534
- FCF yield1.6% · higher than 91% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Anika Therapeutics, Inc.🇺🇸 | $267 M | — | -1.4% | -5.9% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Sep 30, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As on 2021
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Anika Therapeutics, Inc.? Verify and update this profile — free
Show Anika Therapeutics, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.